CIPO Patents = 8

EPO Patents = 1

Forward Citations = 6

Loading Chart...

8 inventors (with patents filed for the assignee):

Aprile L Pilon (4 out of 13 patents)

Melissa E Winn (2 out of 8 patents)

Humcha K Hariprakasha (1 out of 4 patents)

4. Richard S Clayton (1 out of 4 patents)

5. John K Zehmer (1 out of 3 patents)

6. Aprile L Pilon-Clayton (1 out of 1 patent)

7. Louis Flamand (1 out of 1 patent)

8. Pierre Borgeat (1 out of 7 patents)

5 patents: Sort by Forward Citations

1. 9844580 - Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis (2017-12-19),

2. 9765127 - Compositions and methods of use for recombinant human secretoglobins (2017-09-19),

3. 9394349 - Modification and compositions of human secretoglobin proteins (2016-07-19),

4. 9168285 - Recombinant human CC10 protein for treatment of influenza and ebola (2015-10-27),

5. 8957018 - Recombinant human CC10 protein for treatment of influenza (2015-02-17),

Therabron Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for respiratory diseases. Their innovative approach includes a pipeline of drug candidates targeting important unmet needs in the treatment of respiratory conditions. Therabron Therapeutics is committed to improving the lives of patients with respiratory diseases through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

5 Patents

#99 in Rockville, MD

#724 in Maryland

#50,165 in US

Rockville, MD, United States of America

Therabron Therapeutics, Inc.

Forward Citations = 6

8 inventors:

Aprile L Pilon (4 out of 13 patents)

Melissa E Winn (2 out of 8 patents)

Humcha K Hariprakasha (1 out of 4 patents)

4. Richard S Clayton (1 out of 4 patents)

5. John K Zehmer (1 out of 3 patents)

Please report any incorrect information to support@idiyas.com

8 patents (CIPO):

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com